In:
Mycoses, Wiley
Abstract:
The broad‐spectrum antifungal isavuconazole is administered to treat invasive aspergillosis and mucormycosis. Objectives Isavuconazole plasma concentrations in critically ill ICU patients with or without COVID‐19 and invasive fungal infection were determined, and factors for sub‐therapeutic drug levels ( 〈 1 μg/mL) were evaluated. Patients and Methods Isavuconazole plasma levels were measured as part of therapeutic drug monitoring (TDM) in ICUs of a tertiary hospital. Concentrations determined 20–28 h after previous dosing were defined as trough (C min ) levels. A total of 160 C min levels from 62 patients with invasive fungal infections were analysed, 30 of which suffering from COVID‐19. Patient characteristics included into univariable and multivariable analyses were gender, age, COVID‐19 status, body mass index (BMI), sepsis‐related organ failure (SOFA) score, renal replacement therapy (RRT) and extracorporeal membrane oxygenation (ECMO) requirement. Results The mean C min of isavuconazole in all patients was 1.64 μg/mL (interquartile range 0.83–2.24 μg/mL, total range 0.24–5.67 μg/mL). In total, 34.4% of the C min values (corresponding to 46.8% of patients) were below a threshold concentration of 1 μg/mL. Drug concentrations between patients with or without COVID‐19 did not differ ( p = .43). In contrast, levels were significantly lower in patients with female sex ( p = .0007), age ≤ 65 years ( p = .002), BMI 〉 25 ( p = .006), SOFA score 〉 12 ( p = .026), RRT ( p = .017) and ECMO requirement ( p = .001). Conclusions Isavuconazole plasma levels can be negatively affected by patients' risk factors, supportive renal replacement and ECMO therapy. Future prospective studies analysing the relevance of isavuconazole drug levels in ICU patient outcome are urgently needed.
Type of Medium:
Online Resource
ISSN:
0933-7407
,
1439-0507
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
2020780-3
Permalink
